Expertise in
6
conditions
Expertise in
6
conditions
MedStar Georgetown Cancer Institute At MedStar Georgetown University Hospital
3800 Reservoir Rd NW, 
Washington, DC 

Overview

Jeffrey Toretsky is a Hematologist and an Oncologist in Washington, Washington, D.c.. Dr. Toretsky is highly rated in 6 conditions, according to our data. His top areas of expertise are Ewing Sarcoma, Osteosarcoma, Adult Soft Tissue Sarcoma, Rhabdomyosarcoma, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 72 peer reviewed articles and participating in 35 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in DC

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

MedStar Georgetown Cancer Institute at MedStar Georgetown University Hospital
3800 Reservoir Rd NW, Washington, DC 20007

Additional Areas of Focus

Dr. Toretsky has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


35 Clinical Trials

A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine (DFMO) in Children With Relapsed, Refractory or Progressive Neuroblastoma
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
Neuroblastoma Biology Studies
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Renal Tumors Classification, Biology, and Banking Study
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
View 31 Less Clinical Trials
Similar Doctors
Expertise in
19
conditions
Hematology | Oncology
Expertise in
19
conditions
Hematology | Oncology

Office

9609 Medical Center Dr, 
Bethesda, MD 
 (6.1 miles away)
Languages Spoken:
English

Sharon Savage is a Hematologist and an Oncologist in Bethesda, Maryland. Dr. Savage is highly rated in 19 conditions, according to our data. Her top areas of expertise are Dyskeratosis Congenita, Aplastic Anemia, Aase Syndrome, Hormone Replacement Therapy (HRT), and Bone Marrow Transplant.

Expertise in
13
conditions
Hematology | Oncology
Expertise in
13
conditions
Hematology | Oncology

Office

9609 Medical Center Dr Rm 6E452, 
Rockville, MD 
 (13.7 miles away)
Languages Spoken:
English

Blanche Alter is a Hematologist and an Oncologist in Rockville, Maryland. Dr. Alter is highly rated in 13 conditions, according to our data. Her top areas of expertise are Aase Syndrome, Dyskeratosis Congenita, Aplastic Anemia, Bone Marrow Transplant, and Hormone Replacement Therapy (HRT).

Expertise in
7
conditions
Hematology | Oncology
Expertise in
7
conditions
Hematology | Oncology

Dept Of Transfusion Medicine/Nih Clinical Center

10 Center Dr, 
Bethesda, MD 
 (6.5 miles away)
Languages Spoken:
English

Javed Khan is a Hematologist and an Oncologist in Bethesda, Maryland. Dr. Khan is highly rated in 7 conditions, according to our data. His top areas of expertise are Rhabdomyosarcoma, Adult Soft Tissue Sarcoma, Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, and Angioplasty.

Frequently Asked Questions about Dr. Jeffrey Toretsky

How do I make an appointment with Dr. Jeffrey Toretsky?

You can book an appointment with Dr. Jeffrey Toretsky by calling their office at 202-444-2223. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jeffrey Toretsky a top-rated expert for Ewing Sarcoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jeffrey Toretsky is classified as an Elite expert for Ewing Sarcoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jeffrey Toretsky specialize in?

While Dr. Jeffrey Toretsky is a Hematology, they have specific expertise in Ewing Sarcoma, Osteosarcoma, and Adult Soft Tissue Sarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Jeffrey Toretsky participate in research or clinical trials?

Yes. Dr. Jeffrey Toretsky has published 72 articles and abstracts on conditions like Ewing Sarcoma. You can view a list of Dr. Jeffrey Toretsky's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jeffrey Toretsky accept my insurance?

Dr. Jeffrey Toretsky accepts most major insurance plans, including CareFirst and Cigna. We recommend calling the office directly at 202-444-2223 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Toretsky's expertise for a condition
ConditionClose
    View All 16 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile